Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Clinical Microbiology and Infectious Diseases

• Publication date

  2017-07-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10096-017-3063-zPMID 28748397
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.

  2017cited by this paper
• Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

  2016cited by this paper
• Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function

  2016cited by this paper
• Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

  2016cited by this paper
• Co-occurrence of extended spectrum β lactamase and MCR-1 encoding genes on plasmids.

  2016cited by this paper
• Trojan Horse Antibiotics—A Novel Way to Circumvent Gram-Negative Bacterial Resistance?

  2016cited by this paper
• Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study.

  2016cited by this paper
• In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

  2016cited by this paper
• Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli.

  2016cited by this paper
• In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

  2015cited by this paper
• Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015.

  2015cited by this paper
• Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

  2011cited by this paper
• Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

  2011cited by this paper
• Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

  2008cited by this paper
• Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern

  2008cited by this paper
• Bacterial resistance: origins, epidemiology, and impact.

  2003cited by this paper
• Extended-spectrum -lactamases

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Extended-spectrum beta-lactamases

  1989cited by this paper
• Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens

  1983cited by this paper

• IN VITRO EVALUATION OF THE COMBİNATION OF CEFTOLOZANE/TAZOBACTAM AND COLISTIN IN INTENSIVE CARE UNIT–ASSOCIATED MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII INFECTIONS

  2026cites this paper
• The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review

  2025cites this paper
• How I manage patients with New Delhi metallo-beta-lactamase and OXA-48-producing Enterobacterales infections: a practical approach

  2025cites this paper
• In vitro activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant Acinetobacter baumannii

  2025cites this paper
• Cefiderocol in Combination With Trimethoprim-sulfamethoxazole for Multidrug-resistant Stenotrophomonas maltophilia Ventilator-associated Pneumonia in an Extremely Preterm Infant: A Case Report.

  2025cites this paper
• Antibiotic conjugates: Using molecular Trojan Horses to overcome drug resistance.

  2025cites this paper
• An Assessment Of Cefiderocol's Synergistic Effects With Eravacycline, Colistin, Meropenem, Levofloxacin, Ceftazidime/avibactam, And Tobramycin Against Carbapenem-Resistant and -Susceptible Pseudomonas aeruginosa.

  2025cites this paper
• Febrile neutropenia management in high-risk neutropenic patients: a narrative review on antibiotic prophylaxis and empirical treatment

  2025cites this paper
• Case Report on Cefiderocol-Non-Susceptible Escherichia Coli in the Absence of Carbapenemase Genes

  2025cites this paper
• Insights into the activity of cefiderocol against PER-2 producing Enterobacterales

  2024cites this paper
• Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii

  2024cites this paper
• In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii carrying various β-lactamase encoding genes

  2024influential citation
• Distinct chromosomal mutation associated with cefiderocol resistance in Acinetobacter baumannii: a combined bioinformatics and mass spectrometry approach to unveil and validate the in vivo-acquired chemoresistance

  2024cites this paper
• Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.

  2024cites this paper
• Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?

  2024cites this paper
• Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies

  2024cites this paper
• Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak

  2024cites this paper
• Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.

  2024cites this paper
• In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations

  2024cites this paper
• Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains

  2024cites this paper
• Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.

  2023cites this paper
• Cefiderocol: Clinical application and emergence of resistance.

  2023cites this paper
• How to treat severe Acinetobacter baumannii infections

  2023cites this paper
• Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies

  2023cites this paper
• New alternative therapeutic strategies against Pseudomonas aeruginosa, an opportunistic multi-resistant pathogen with a myriad of virulence factors

  2023cites this paper
• Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility

  2023cites this paper
• Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.

  2023cites this paper
• The prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence.

  2023cites this paper
• In Vitro Activity of Cefiderocol Compared to Other Antimicrobials against a Collection of Metallo-Beta-Lactamase-Producing Gram-Negative Bacilli from Southern Spain

  2023cites this paper
• An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance

  2023cites this paper
• β-Lactam Resistance in ESKAPE Pathogens Mediated Through Modifications in Penicillin-Binding Proteins: An Overview

  2023cites this paper
• Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

  2023cites this paper
• Proteomic and Transcriptomic Analyses Indicate Reduced Biofilm-Forming Abilities in Cefiderocol-Resistant Klebsiella pneumoniae

  2022cites this paper
• Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019–2021): emergence of complex resistance phenotypes

  2022cites this paper
• Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

  2022cites this paper
• Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics.

  2022cites this paper
• In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.

  2022cites this paper
• In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium

  2022cites this paper
• Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections

  2022cites this paper
• Early appropriate diagnostics and treatment of MDR Gram-negative infections

  2022cites this paper
• Drug development concerning metallo-β-lactamases in gram-negative bacteria

  2022influential citation
• Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials

  2022cites this paper
• Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018).

  2022cites this paper
• Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?

  2022cites this paper
• Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).

  2022cites this paper
• Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019–2020)

  2022cites this paper
• Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens

  2022cites this paper
• Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

  2022cites this paper
• The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition

  2022cites this paper
• Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa

  2022cites this paper
• Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review

  2022cites this paper
• Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Acinetobacter baumannii Clinical Isolates

  2022cites this paper
• Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms

  2021cites this paper
• The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group

  2021cites this paper
• Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.

  2021cites this paper
• Compassionate use of Cefiderocol for VIM Metallo-ß-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma.

  2021cites this paper
• Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?

  2021influential citation
• An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date

  2021cites this paper
• Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design.

  2021cites this paper
• An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients

  2021cites this paper
• Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii

  2021cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol

  2021cites this paper
• Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections

  2021cites this paper
• In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects

  2021cites this paper
• An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients

  2021cites this paper
• Ceftazidime-avibactam: are we safe from class A carbapenemase producers’ infections?

  2021cites this paper
• Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates.

  2021cites this paper
• Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy Is Associated with Increased blaNDM-5 Copy Number and Gene Expression.

  2021cites this paper
• Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales

  2021cites this paper
• In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples

  2021cites this paper
• In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

  2021cites this paper
• Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.

  2021cites this paper
• In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.

  2020cites this paper
• New treatment options for multiresistant gram negatives.

  2020influential citation
• Natural Inhibitors of Quorum-Sensing Factors: a Novel Strategy to Control Pathogenic Bacteria

  2020cites this paper
• Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens

  2020cites this paper
• Approach and Management of Severe Infections in Neutropenic Patients

  2020cites this paper
• Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety

  2020cites this paper
• Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin

  2020cites this paper
• A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches.

  2020cites this paper
• Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance.

  2020cites this paper
• Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria.

  2020cites this paper
• Cefiderocol: A Siderophore Cephalosporin

  2020cites this paper
• Cefiderocol as Adjunctive Treatment of Necrotizing Ventilator-associated Pneumonia Due to Extensively Drug-Resistant Pseudomonas aeruginosa

  2020cites this paper
• Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens

  2020cites this paper
• Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively- and pan-resistant Acinetobacter baumannii.

  2020cites this paper
• Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli

  2020cites this paper
• [In-vitro Activity of Ceftolozane-Tazobactam in Combination with Various Antibiotics Against Multidrug-resistant Acinetobacter baumannii Isolated from Intensive Care Patients].

  2020cites this paper
• In vivo emergence of resistance to cefiderocol in an XDR Pseudomonas aeruginosa and an MDR Citrobacter koseri after prolonged therapy: a case report.

  2020cites this paper
• Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems

  2020cites this paper
• Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

  2020influential citation
• Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol

  2020cites this paper
• Overcoming Antibiotic Resistance: New Perspectives

  2020cites this paper
• Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective

  2020cites this paper
• Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data

  2020cites this paper
• Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptibleEscherichia colibloodstream infection

  2020cites this paper
• Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine

  2020cites this paper
• Key Takeaways From the U.S. CDC’s 2019 Antibiotic Resistance Threats Report for Frontline Providers

  2020cites this paper
• Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

  2020cites this paper
• Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a novel siderophore cephalosporin

  2020cites this paper